- Home
- ILPT vs ENGN Comparison
ILPT vs ENGN Comparison
Compare ILPT & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILPT
- ENGN
- Stock Information
- Founded
- ILPT 2017
- ENGN 1999
- Country
- ILPT United States
- ENGN Canada
- Employees
- ILPT N/A
- ENGN N/A
- Industry
- ILPT Real Estate Investment Trusts
- ENGN
- Sector
- ILPT Real Estate
- ENGN
- Exchange
- ILPT Nasdaq
- ENGN Nasdaq
- Market Cap
- ILPT 174.6M
- ENGN 199.7M
- IPO Year
- ILPT 2018
- ENGN N/A
- Fundamental
- Price
- ILPT $3.31
- ENGN $3.95
- Analyst Decision
- ILPT Buy
- ENGN Buy
- Analyst Count
- ILPT 2
- ENGN 7
- Target Price
- ILPT $10.00
- ENGN $23.29
- AVG Volume (30 Days)
- ILPT 371.9K
- ENGN 93.7K
- Earning Date
- ILPT 04-29-2025
- ENGN 06-13-2025
- Dividend Yield
- ILPT 1.22%
- ENGN N/A
- EPS Growth
- ILPT N/A
- ENGN N/A
- EPS
- ILPT N/A
- ENGN N/A
- Revenue
- ILPT $441,992,000.00
- ENGN N/A
- Revenue This Year
- ILPT $3.09
- ENGN N/A
- Revenue Next Year
- ILPT $1.79
- ENGN N/A
- P/E Ratio
- ILPT N/A
- ENGN N/A
- Revenue Growth
- ILPT 0.61
- ENGN N/A
- 52 Week Low
- ILPT $2.45
- ENGN $2.65
- 52 Week High
- ILPT $5.45
- ENGN $12.80
- Technical
- Relative Strength Index (RSI)
- ILPT 55.89
- ENGN 48.79
- Support Level
- ILPT $3.01
- ENGN $3.85
- Resistance Level
- ILPT $3.41
- ENGN $4.42
- Average True Range (ATR)
- ILPT 0.15
- ENGN 0.45
- MACD
- ILPT 0.01
- ENGN 0.08
- Stochastic Oscillator
- ILPT 44.44
- ENGN 65.75
About ILPT Industrial Logistics Properties Trust of Beneficial Interest
Industrial Logistics Properties Trust is a real estate investment trust. It owns and leases industrial and logistics properties throughout the United States. The company's investment portfolio includes industrial lands in Hawaii and industrial and logistics properties in other states. Rental revenue is earned from Hawaii Properties and Mainland Properties.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.